Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
about
Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanismsThe importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseMultiple Aspects of Gene Dysregulation in Huntington's DiseaseGlutamate and neurotrophic factors in neuronal plasticity and diseaseHuman accelerated region 1 noncoding RNA is repressed by REST in Huntington's diseaseThe Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.Ethanol-BDNF interactions: still more questions than answers.Localization of BDNF mRNA with the Huntington's disease protein in rat brain.Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during agingA neuroprotective phase precedes striatal degeneration upon nucleolar stress.BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior.Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation.Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model miceAltered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system.BDNF signaling and survival of striatal neurons.Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads databaseBDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 miceDifferential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease.Abnormal motor cortex plasticity in premanifest and very early manifest Huntington diseaseAbnormal motor cortex excitability in preclinical and very early Huntington's disease.Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease.ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease.Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases.In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.Dominant effects of the Huntington's disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategyTranscription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspectiveA monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.HD CAGnome: a search tool for huntingtin CAG repeat length-correlated genesHuntington's Disease and Striatal Signaling.Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.Cellular therapy and induced neuronal replacement for Huntington's disease.MicroRNA-124 slows down the progression of Huntington's disease by promoting neurogenesis in the striatum.Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington's disease are not reflected in mutant Huntingtin inclusion prevalence.Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model miceThe group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease micePotential drugs and methods for preventing or delaying the progression of Huntington's disease.
P2860
Q21131050-28625723-991A-49CA-9746-C1821CE2DC9FQ22306292-14019AC5-19F1-406D-84A4-9031F50CB456Q24605880-C83A5603-369E-434F-97D0-4BAF4DDAF253Q24653626-A0215392-8F80-49B2-9A4C-9B9474A1964FQ28274070-2DFBF3DB-F148-4805-A7C8-D55B4498F25DQ28571426-EE05F2A7-AEB5-48C2-AE1F-EB53E18E47B7Q30401432-75FD1B55-838C-45EE-92C4-E189220AA201Q30490427-43414978-730A-4788-8556-5654AD715AB9Q30495033-7E89BDD7-6868-4BEA-9416-6ACF1F49B1ADQ30497994-23D8F7E2-E60D-4EDE-BA63-77D8929B7849Q30549660-B8A3EAE1-8612-4109-971A-BA4AAC044142Q30573241-20CEA03E-BD3E-4054-821A-9CEAEE312B02Q33434423-A8301813-CBF3-48D5-A80B-947D19A67AF7Q33781761-EC579CCB-4044-43E3-8E05-3607E07161E2Q34071987-F0608F1F-0D7B-44B3-B2D4-32D4DAE75047Q34102098-9B5F0CF3-B084-40F5-ABA3-8E3EEE0F3E64Q34189409-49CDE269-4C0F-4D9C-A8A5-414FB9A63989Q34319766-3D8CC4A7-2B65-42E4-84D8-19D27911ACF1Q34338809-71CF369F-AE11-42E6-B707-F4EFC7FDAC68Q34341619-322DFE34-7407-4821-BCE0-12891676BBCDQ34382326-488B4392-BC22-4FDD-B500-78236FAAD90CQ34386162-354373C7-2BB9-4EA3-BB51-1B753F92FE08Q34406937-776BB718-61B1-4604-988D-03EAEC39B7B8Q34424253-FDB2733A-96B4-4FD3-B5DF-E538F5BFFECDQ34440282-A1F659C2-6766-474D-AE38-01F9B338520DQ34505628-D7D6AF28-8E59-41C0-9C83-ADA34EF8DCB2Q34567939-70F70CA5-D11D-4101-B612-DDB4F4E52909Q34597796-82792091-EA42-47B7-8989-6EB30A304467Q34675885-2473E7DF-4720-48EC-9EF0-8C118F9DBADCQ35024695-DB64459F-E340-415A-893D-6105803E2B04Q35087700-8A9CE5A3-E4DB-41A1-89DB-22DD55A9EBCEQ35153990-F510B130-4DC4-48B6-8BFD-076D9DFCBE8FQ35286098-57841CA2-5C28-4CF1-8251-574650C0781EQ35487248-4EA778CF-9CB1-43A2-ACFE-E715E0DE7D39Q35648164-D2D86A50-6C98-4B07-954C-F5E324C9D3E8Q35746332-7C1795AF-0CAB-4E5B-A919-F514B5C6F6B7Q35874743-81353A82-70D9-431E-9668-C10E2D3A0382Q35982759-B94308E0-1109-482A-8CF3-A15C2A93874BQ36037085-BD937772-53BB-4A51-968C-DA7A1310604BQ36142706-D2FC80CB-D238-4B10-9625-94BAA092FA5A
P2860
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Expression profiling of Huntin ...... role in striatal degeneration.
@ast
Expression profiling of Huntin ...... role in striatal degeneration.
@en
Expression profiling of Huntin ...... role in striatal degeneration.
@nl
type
label
Expression profiling of Huntin ...... role in striatal degeneration.
@ast
Expression profiling of Huntin ...... role in striatal degeneration.
@en
Expression profiling of Huntin ...... role in striatal degeneration.
@nl
prefLabel
Expression profiling of Huntin ...... role in striatal degeneration.
@ast
Expression profiling of Huntin ...... role in striatal degeneration.
@en
Expression profiling of Huntin ...... role in striatal degeneration.
@nl
P2093
P1476
Expression profiling of Huntin ...... role in striatal degeneration.
@en
P2093
Aaron K Aragaki
Andrew D Strand
Charles Kooperberg
James M Olson
Kevin R Jones
Lesley Jones
Lichuan Yang
M Flint Beal
Zachary C Baquet
P304
11758-11768
P356
10.1523/JNEUROSCI.2461-07.2007
P407
P577
2007-10-01T00:00:00Z